Dr Joseph Gray
Dr Dipanker Chattopadhyay
Dr Gary Beale
Dr Gillian Patman
Dr Luca Miele
et al. | A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease | 2009 |
|
Dr Ellen Hatch
Elizabeth Sconce
Dr Barry King
Dr Hilary Wynne
Professor Ann Daly
et al. | Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement | 2007 |
|
Emerita Professor Ann Daly
Dr Barry King
| Contribution of CYP2C9 to variability in vitamin K antagonist metabolism | 2006 |
|
Emerita Professor Ann Daly
Dr Barry King
Julian Leathart
| Genotyping for cytochrome P450 polymorphisms | 2006 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
| [abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Patrick Kesteven
Dr Peter Avery
et al. | [abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Barry King
et al. | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen | 2005 |
|
Dr Barry King
Dr Pamela MacDonald
Dr Dipanker Chattopadhyay
Professor Helen Reeves
| The Kruppel-like factor 6 tumour suppressor induces apoptosis in HepG2 cells | 2005 |
|
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Dr Patrick Kesteven
Peter Wood
et al. | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | 2004 |
|
Professor Ann Daly
Dr Barry King
| CYP3A5 phenotype-genotype correlations in a British population - Response | 2004 |
|
Emerita Professor Ann Daly
Dr Barry King
| Genotyping of the A6986G polymorphism of CYP3A5 | 2004 |
|
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Professor Ann Daly
Dr Hilary Wynne
et al. | The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements | 2004 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Emerita Professor Ann Daly
| Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism | 2004 |
|
Dr Barry King
Julian Leathart
Dr Elaine Mutch
Professor Faith Williams
Professor Ann Daly
et al. | CYP3A5 phenotype-genotype correlations in a British population | 2003 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
| Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements | 2003 |
|
Emerita Professor Ann Daly
Dr Barry King
| Pharmacogenetics of oral anticoagulants | 2003 |
|
